We’re thrilled to share the publication of our latest paper in Communications Medicine, detailing the promising results of our phase 2 study on AB002, a novel protein C activating enzyme. This proof-of-concept study opens new doors for safely managing thrombosis in vulnerable patient populations. Our phase 2 trial highlights AB002's potential as a safe and effective alternative to prevent blood clots in end-stage renal disease (ESRD) patients undergoing hemodialysis. Unlike traditional prophylactic options like heparin, which can be contraindicated in some ESRD cases, AB002 demonstrated excellent safety and tolerability in our study, with no treatment-related adverse events or clinically relevant bleeding observed.
Aronora, Inc.
制药业
Portland，Oregon 643 位关注者
Next generation therapeutics for blood clotting diseases
关于我们
Aronora is a translational biotechnology company (aronorabio.com) engaged in the development of proprietary biologic therapeutics, including recombinant monolconal antibodies and enzymes. Rational design of our innovative therapeutic agents is expected to result in drug products that reduce the progression and growth of life-threatening blood clots without the detrimental bleeding side effects that characterize all currently marketed antithrombotic drugs. Our products are intended to be used in difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases.
- 网站
-
https://aronorabio.com/
Aronora, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Portland，Oregon
- 类型
- 私人持股
- 创立
- 2009
- 领域
- hematology
地点
-
主要
获取路线
1818 SW 4th Ave
Suite 102
US，Oregon，Portland，97201
Aronora, Inc.员工
动态
-
?? Exciting news in cardiology and anticoagulants! A new class of anticoagulants targeting factor XI aims to prevent or reduce blood clots without increasing bleeding risks. NYBC Ventures is thrilled about our (not so) closely held portfolio company Aronora, Inc. involvement in this groundbreaking development. Factor XI inhibitors show promise in revolutionizing anticoagulation therapy, offering hope for improved patient outcomes. Stay tuned for updates as we follow the progress of this innovation! #Cardiology #Anticoagulants #Innovation #MedicalResearch https://lnkd.in/gurDEGkE
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
wsj.com
-
FEATURED ARTICLE: Inhibition of FXI reduced incidence of thrombosis during central line placement with no significant adverse bleeding https://lnkd.in/gkeDfnhJ
-
-
Inhibition of FXI reduced incidence of thrombosis during central line placement with no significant adverse bleeding @mikeapfeffer @clotmaster @bloodman @svematologist https://lnkd.in/gkeDfnhJ
-